BERLIN and SEATTLE, May 3, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) today announced that its Management Board and Supervisory Board decided to increase the company's share capital against contribution in cash without subscription rights. Epigenomics intends to place up to 1,335,526 new shares through a private placement with institutional and private investors in Europe and a limited number of selected institutional buyers and accredited investors the U.S. The new shares will represent approximately 7.9% of Epigenomics' currently issued share capital. DZ Bank (Frankfurt, Germany) will coordinate the listing process.